


# ADVANCED HEART FAILURE SYMPOSIUM

SATURDAY  
OCTOBER 19  
MARRIOTT MARQUIS  
WASHINGTON, DC



**INOVA**<sup>®</sup>

Heart and Vascular Institute

Approved for CME Credits: *AMA PRA Category 1 Credit*<sup>™</sup>  
7 ABIM MOC Points  
8.4 Nursing Contact Hours

## Program Description

---

The ***Inova Heart and Vascular Institute 2019 Advanced Heart Failure Symposium*** will provide a review of best practices in the field of heart failure, including current guidelines, co-morbidities with a particular emphasis on diabetes, innovative and novel pharmacological and technological treatment options and health policy concerns. The role of mechanical support, the differences in the types of devices, possible complications, and the latest thinking on home monitoring, surgical approaches and transplantation will be presented and discussed in detail to help physicians and healthcare providers make better informed decisions regarding referral for transplant or mechanical cardiac support.

Through interactive lectures, case studies and panel discussions, world renowned experts will present the very latest research and clinical trial results with an emphasis on the application to day to day clinical practice.

The program will cover the following general topics:

- Guideline Directed Medical Therapy and Novel Approaches to Heart Failure Management
- Cutting Edge Device Therapy for Heart Failure
- Treatment Options for Advanced Heart Failure
- New insights on the Management of Amyloid, HOCM, and other interesting clinical cases

## Target Audience

---

- Heart Failure specialists
- Cardiovascular clinicians
- Primary care physicians, hospitalists
- Fellows and residents in training
- Advanced practice nurses and other non-physician members of the cardiac care team

## Educational Objectives

---

Upon completion of this course, participants should be able to:

- Understand and apply novel approaches and new pharmacological treatment options for the management of heart failure
- Utilize novel treatments for mitral regurgitation, comorbidities, and arrhythmias appropriately
- Delineate the best practices for when to refer advanced heart failure patients for evaluation for heart transplant or mechanical cardiac support

## CME Accreditation Statement

---

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the Joint Providership of the The University of Massachusetts Medical School and Inova Heart and Vascular Institute. The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## Designation Statement

---

The University of Massachusetts Medical School designates this live activity for a maximum of *7 AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only credit commensurate with the extent of their participation in the activity.

## ABIM MOC

---

Earn up to 7 ABIM MOC Points.

## Nursing Contact Hours

---

This live activity meets the requirements for up to 8.4 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04).



## Endorsement

---

The 2019 IHVI Advanced Heart Failure Symposium is officially endorsed by the Heart Failure Society of America.

The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the HFSA.



# FRIDAY, OCTOBER 18, 2019

6:00 – 7:15 PM

WELCOME AND NETWORKING RECEPTION

# SATURDAY, OCTOBER 19, 2019

7:30 – 8:00 AM

REGISTRATION, COFFEE, EXHIBITS

8:00 – 8:05 PM

**OPENING REMARKS**

*Christopher M. O'Connor, MD*

8:05 – 9:00 AM

**Improving Outcomes in Cardiogenic Shock**

*Moderator: Shashank Desai, MD*

8:05 – 8:15 AM

**Why do We Care about Cardiogenic Shock?**

*Carolyn Rosner, RN*

8:15 – 8:25 AM

**What has been done to Treat Cardiogenic Shock?**

*Alexander Truesdell, MD*

8:25 – 8:35 AM

**How is Cardiogenic Shock Managed at IHVI and how has that Changed Outcomes**

*Behnam Tehrani, MD*

8:35 – 9:00 AM

**Panel Discussion**

*Carolyn Rosner, Shashank Sinha, Behnam Tehrani, Alex Truesdell*

9:00 – 9:05 AM

**Keynote Introduction**

*Christopher M. O'Connor, MD*

9:05 – 9:50 AM

**KEYNOTE LECTURE**

**SGLT2i for Heart Failure: An Update in a Rapidly Moving Field**

*Eugene Braunwald, MD*

9:55 – 11:15 AM

**DRUG THERAPY FOR HEART FAILURE**

*Moderators: Michael Bristow, MD, PhD; Mona Fiuza, PharmD*

9:55 – 10:05 AM

**The Current State of Heart Failure: How are We Doing?**

*Mariell Jessup, MD*

10:05 – 10:15 AM

**Current Management Strategies in HFpEF**

*Peter Carson, MD*

10:15 – 10:25 AM

**What's New in the AHA/ACC/HFSA Guidelines**

*Clyde Yancy, MD*

10:25 – 10:35 AM

**Managing Chronic HF**

*G. Michael Felker, MD*

10:35 – 10:45 AM

**Anticoagulation in the HF Patient**

*John Teerlink, MD*

10:45 – 10:55 AM

**Managing RV Failure and Pulmonary Hypertension**

*Mitchell Psozka, MD, PhD*

10:55 – 11:15 AM

**Panel Discussion**

*Peter Carson, G. Michael Felker, Mariell Jessup, Mitchell Psozka, John Teerlink, Clyde Yancy*

**SESSION 1: DRUG THERAPY**

11:15 - 11:35 AM

**EXHIBIT AND NETWORKING BREAK, POSTERS**

**SESSION 2:  
DEVICES**

11:35 – 1:00 PM

**CUTTING EDGE DEVICE THERAPY FOR HEART FAILURE**

Moderators: *Peter Carson, MD; Melvin Echols, MD*

11:35 – 11:45 AM

**Novel Device Therapies for HF**

*William Abraham, MD*

11:45 – 11:55 PM

**Hemodynamic Monitoring in the Modern Era**

*Lauren Cooper, MD*

11:55 – 12:05 PM

**Interventional Heart Failure**

*Wayne Batchelor, MD*

12:05 – 12:15 PM

**Mitral Regurgitation: Interpreting COAPT and MITRA-FR**

*JoAnn Lindenfeld, MD*

12:15 – 12:25 PM

**Device Considerations in Special Populations**

*Mariell Jessup, MD*

12:25 – 12:35 PM

**Managing HF Patients after ICD/CRT Implantation**

*Amrut Ambardekar, MD*

12:35 – 1:00 PM

**Panel Discussion**

*Amrut Ambardekar, Wayne Batchelor, Lauren Cooper, JoAnn Lindenfeld, Mariell Jessup, Patient*

**LUNCH**

1:00 – 1:55 PM

**LUNCH, EXHIBITS AND NETWORKING**

1:20 – 1:45 PM

**Poster Session**

Moderators / Judges

*Lauren Cooper, MD; Christopher deFilippi, MD; Mitchell Psotka, MD, PhD; Palak Shah, MD;*

2:00 – 3:15 PM

**SPECIAL POPULATIONS AND INTERESTING CASES**

Moderators: *Christopher M. O'Connor, MD; Palak Shah, MD*

2:00 – 2:10 PM

**Peripartum/Post-Partum Cardiomyopathy**

*JoAnn Lindenfeld, MD*

2:10 – 2:20 PM

**Cardio-Oncology**

*Bonnie Ky, MD*

2:20 – 2:30 PM

**Amyloid**

*Mathew Maurer, MD*

2:30 – 2:40 PM

**Heart Failure in Women**

*Kelly Epps, MD*

2:40 – 2:50 PM

**Heart Failure in the Elderly**

*Tariq Ahmad, MD*

2:50 - 3:15 PM

**Interesting Clinical Cases with Panel Discussion**

Presenter: *Nasrien Ibrahim, MD*

**Panelists:**

*Tariq Ahmad, Kelly Epps, Bonnie Ky, JoAnn Lindenfeld, Mathew Maurer*

**SESSION 3:  
SPECIAL POPULATIONS**

**SESSION 4:  
ADVANCED HF**

**3:15 - 3:30 PM EXHIBIT AND NETWORKING BREAK, POSTERS**

**3:30 – 4:40 PM CUTTING EDGE CONCEPTS IN ADVANCED HEART FAILURE**

Session Moderator: *Robert Cole, MD; Daniel Tang, MD*

**3:30 – 3:40 PM Impact of the New Allocation System**

*Joseph Rogers, MD*

**3:40 – 3:50 PM HF Referrals: Timing is Key**

*Shashank Desai, MD*

**3:50 – 4:00 PM End Stage Heart Failure: ECMO and Beyond**

*Robert Cole, MD*

**4:00 – 4:10 PM Management of LVAD patients for the Non-LVAD Specialist**

*Tariq Ahmad, MD*

**4:10 – 4:20 PM Cutting Edge Concepts in Surgical Options**

*Daniel Tang, MD*

**4:20 – 4:40 PM Panel Discussion**

*Tariq Ahmad, Lauren Cooper, Shashank Desai, Joseph Rogers, Palak Shah*

**4:40– 4:55 PM POSTER AWARDS, RAFFLE WINNERS, CLOSING REMARKS**

*Christopher M. O'Connor, MD*



**Eugene Braunwald, MD**  
Keynote Speaker



**Christopher O'Connor, MD**  
Course Director



**Shashank Desai, MD**  
Co-Chair



**Mona Fiuzat, PharmD**  
Co-Chair

**FACULTY**

**William Abraham, MD, FACC, FAHA, FESC**

Professor of Medicine, Physiology, and Cell Biology  
Associate Dean for Clinical Research  
Director, Clinical Trials Management Office  
Deputy Director, Davis Heart and Lung  
Research Institute  
The Ohio State University

**Tariq Ahmad, MD, MPH, FACC**

Advanced Heart Failure and Transplant  
Assistant Professor of Medicine  
Yale New Haven Health System

**Amrut V. Ambardekar, MD, FACC, FHFSA**

Medical Director Cardiac Transplant Program  
Director of Clinical Research  
Division of Cardiology  
University of Colorado

**Wayne Batchelor, MD, MHS, FACC, FSCAI**

Director of the Interventional Heart Program,  
Inova Health System  
Director of Interventional Heart Disease Research,  
Education, and Innovation  
Associate Director  
Inova Heart and Vascular Institute

**Eugene Braunwald, MD, MACC, FAHA, FESC**

Distinguished Hersey Professor of Medicine  
Harvard Medical School  
Founding Chairman of the TIMI Study Group  
Brigham and Women's Hospital

**Michael Bristow, MD, PhD, FACC, FHFSA**

Professor of Medicine (Cardiology)  
Director of Pharmacogenomics  
University of Colorado Division of Cardiology  
President and CEO  
ARCA Biopharma

**Peter Carson, MD, FACC**

Clinical Professor of Medicine Georgetown University  
Director, Heart Failure Program  
Washington DC VA Medical Center

**Robert Cole, MD, FACC, FHFSA**

Director, Heart Failure Section IHVI  
Director, Inova Heart Failure Site Based Research  
Inova Heart and Vascular Institute

**Lauren Cooper, MD, MHS, FACC, FHFSA**

Director of Heart Failure Disease Management Clinic  
Associate Director of Heart Failure Research  
Inova Heart and Vascular Institute

**Christopher deFilippi, MD, FACC**

Vice Chair of Academic Affairs,  
Director of Cardiology Fellowship Program  
Inova Heart and Vascular Institute

**Shashank Desai, MD, FACC**

Medical Director, Advanced Heart Failure and  
Transplant Program, Inova Health System  
Inova Heart and Vascular Institute

**Melvin R. Echols, MD, FACC**

Assistant Professor of Medicine  
Department of Cardiology  
Program Director, Cardiovascular Disease Fellowship  
Camp Creek Cardiovascular Disease Clinic

**Kelly Epps, MD, MSHP, FACC**

Interventional Cardiology, Cardiovascular Disease  
Inova Heart and Vascular Institute

**G. Michael Felker, MD, FACC, FHFSa**

Chief, Heart Failure Section  
Director, Heart Failure Research, DCRI  
Professor of Medicine  
Duke University

**Mona Fiuzat, PharmD, FACC, FHFSa, FHFA**

Former Sr. Scientific Advisor to FDA Commissioner  
Associate Professor of Medicine  
Duke University

**Nasrien E. Ibrahim, MD, FACC, FHFSa**

Assistant Professor, Harvard Medical School  
Advanced Heart Failure and Transplant Cardiologist,  
Massachusetts General Hospital

**Mariell Jessup, MD, FACC, FAHA, FHFA**

Emeritus Professor of Medicine  
University of Pennsylvania  
Chief Science and Medical Officer  
American Heart Association

**Bonnie Ky, MD, MSCE, FACC**

Associate Professor of Medicine  
Perelman School of Medicine  
University of Pennsylvania

**JoAnn Lindenfeld, MD, FACC, FAHA, FHFSa**

Director, Heart Failure and Transplant Program  
Professor of Medicine  
Vanderbilt University

**Mathew Maurer, MD, FACC**

Arnold and Arlene Goldstein Professor of Cardiology  
Professor of Medicine  
Columbia University Irving Medical Center Director  
Clinical Cardiovascular Research Laboratory for the Elderly  
New York Presbyterian Hospital

**Christopher O'Connor, MD, MACC, FESC, FHFSa**

President  
Inova Heart and Vascular Institute  
Professor of Medicine  
Duke University

**Mitchell Psozka, MD, PhD**

Advanced Heart Failure, Transplant, and Pulmonary  
Hypertension  
Associate Director Heart Failure Site Based Research  
and Heart Failure Outreach Programs  
Inova Heart and Vascular Institute

**Joseph G. Rogers, MD, FACC, FHFSa**

Professor of Medicine, Division of Cardiology  
Chief Medical Officer  
Duke University Health System

**Carolyn Rosner, RN, MSN, NP-C**

Director IHVI Programs

**Palak Shah, MD, MS, FACC, FHFSa**

Director, Cardiovascular Genomics Center  
Director, Heart Failure Research  
Inova Heart and Vascular Institute  
Assistant Professor of Medicine  
George Washington University

**Shashank Sinha, MD, MSc, FACC**

Advanced Heart Failure & Transplant  
Director, Cardiac Intensive Care Unit  
Inova Heart & Vascular Institute

**Daniel Tang, MD, FACC, FACS**

Chief, Cardiothoracic Transplantation  
Inova Heart and Vascular Institute

**John Teerlink, MD, FACC, FESC, FAHA, FHFSa**

Director, Heart Failure Program and Clinical  
Echocardiography Lab,  
San Francisco VA Medical Center  
Professor of Medicine,  
University of California, San Francisco

**Behnam Tehrani, MD, FACC, FSCAI**

Director, Cardiac Catheterization Laboratory  
Inova Heart and Vascular Institute

**Alexander Truesdell, MD, FACC, FSCAI**

Interventional Cardiologist  
Inova Heart and Vascular Institute


**Clyde Yancy, MD, MACC, FAHA, FHFSa**

Vice Dean for Diversity and Inclusion  
Chief of Cardiology, Department of Medicine  
Northwestern Feinberg School of Medicine

# LVEF Improvement Demonstrated in High-Risk Patients

Several PCI studies utilizing the Impella heart pump, including U.S. Impella Registry, PROTECT I, PROTECT II and the recent Burzotta publication have demonstrated improvement in LVEF<sup>1,4</sup>

## Multiple Studies Highlight Patient Benefits After Protected PCI



1. Maini et al. Catheter Cardiovasc Interv. 2012 Nov 1;80(5):717-25.
2. O'Neill et al. Circulation. 2012 Oct 2;126(14):1712-27.
3. Burzotta et al. Long-Term Outcomes of Extent of Revascularization in Complex High Risk Indicated Patients. JIC. 2019
4. Dixon et al. JACC Cardiovasc Interv. 2009 Feb;2(2):51-6.

All cardiovascular procedures have risk. Potential adverse events associated with the use of Impella include: acute renal dysfunction, aortic valve injury, bleeding, cardiogenic shock, stroke, hemolysis, limb ischemia, myocardial infarction, renal failure, thrombocytopenia, vascular injury and death.

To learn more about the Impella platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: [www.abiomed.com/important-safety-information](http://www.abiomed.com/important-safety-information)

**Impella**  
The Heart's Future



## Creating a healthier future.

Every day, we challenge ourselves to help people suffering from cardiovascular diseases.

Building on a heritage of 120 years of innovation, we are committed to prevention and treatment.

Together, we are making a difference.



# SURVIVAL NEVER LOOKED SO GOOD

## THE WORLD'S SMALLEST CENTRIFUGAL VAD

with more than 18,000 implants worldwide and clinical evidence to prove its safety and effectiveness when used in a less-invasive thoracotomy approach.<sup>1,2</sup>



### References:

1. McGee E, Danter M, et al. Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial. JHLT. 2019;38(4):344-351.
2. Medtronic data on file as of July 2019, and data extrapolated based on source data from: HVAD System Instructions for Use. HeartWare Inc., Framingham, MA, USA 07/18. HeartMate 3 Left Ventricular Assist System, Instructions for Use. Thoratec Corporation, Pleasanton, CA, USA 02/17.

### Brief Statement: HeartWare™ HVAD™ System

#### Indications for Use

The HeartWare™ HVAD™ System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure, either as a Bridge to Cardiac Transplantation (BTT), myocardial recovery, or as Destination Therapy (DT) in patients for whom subsequent transplantation is not planned.

#### Contraindications

The HeartWare System is contraindicated in patients who cannot tolerate anticoagulation therapy.

Refer to the "Instructions for Use" for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions and potential adverse events prior to using this device.

**Caution:** Federal law (USA) restricts these devices to sale by or on the order of a physician.

### Medtronic

14400 NW 60th Ave  
Miami Lakes, FL 33014  
Tel: (305) 364-1402  
Fax: (954) 874-1401

medtronic.com

UC202001492 EN © Medtronic 2019  
Minneapolis, MN. All Rights Reserved.

Printed in the USA. 08/2019 HeartWare, HVAD, Medtronic  
and Medtronic logo are trademarks of Medtronic.

**Medtronic**